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Bendamustine has efﬁcacy in multiple myeloma with a toxicity proﬁle limited to myelosuppression. We
hypothesized that adding bendamustine to autologous stem cell transplant conditioning in myeloma would
enhance response without signiﬁcant additional toxicity. We conducted a phase 1 trial adding escalating
doses of bendamustine to the current standard conditioning of melphalan 200 mg/m2. Twenty-ﬁve subjects
were enrolled into 6 cohorts. A maximum tolerated dose was not encountered and the highest dose level
cohort of bendamustine 225 mg/m2 þ melphalan 200 mg/m2 was expanded to further evaluate safety.
Overall, there was no transplant related mortality and only one grade 4 dose-limiting toxicity was observed.
Median number of days to neutrophil and platelet engraftment were 11 (range, 9 to 14) and 13 (range, 10 to
21), respectively. Disease responses at day þ100 posttransplantation were progression in 5 (21%), partial
response in 1 (4%), very good partial response in 7 (33%), complete response in 1 (4%), and stringent complete
response in 9 (38%). Six patients (24%) with pre-existing high-risk disease died from progressive myeloma
during study follow-up, all at or beyond 100 days after autologous stem cell transplant. Bendamustine up to
a dose of 225 mg/m2 added to autologous stem cell transplantation conditioning with high-dose melphalan in
patients with multiple myeloma did not exacerbate expected toxicities.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by autologous
stem cell transplantation (ASCT) has been a mainstay of
therapy for the treatment of multiple myeloma (MM) since
randomized trials in the 1990s showed superiority to
conventional chemotherapy [1,2]. The role and timing of
ASCT have become more controversial since the advent
of the highly effective novel therapies thalidomide, lenali-
domide, and bortezomib; however, several randomized trials
have shown that ASCT can further improve response rates
and clinical outcomes for eligible MM patients whether
induction is performed with either conventional or novel
therapies [3-5]. Multiple analyses show that complete
response (CR) inMM is a surrogate for extended progression-
free survival (PFS) and overall survival (OS), and ASCT
remains a useful tool to increase CR rate [6-8]. Initial
conditioning regimens evolved quickly early in the devel-
opment of ASCT in MM, starting with combinations of total
body irradiation (TBI) and high-dose melphalan with even-
tual abandonment of the TBI after a randomized study by the
Intergroupe Francophone du Myelome (IFM) showed no
advantage of the TBIþmelphalan 140mg/m2 comparedwith
a less toxic conditioning regimen of melphalan 200 mg/m2
(MEL200) [1]. Since the establishment of MEL200 as the
standard of care, several studies have been undertaken to
attempt to improve on the clinical outcomes of ASCT by
altering conditioning. Strategies including increasing thedgments on page 836.
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plantation and adding the monoclonal anti-interleukin-6
have thus far not convincingly shown superiority to the
standard MEL200 regimen, although a subset of patients
achieving less than very good partial response may beneﬁt
from more chemotherapy [9]. The addition of oral busulfan
to melphalan has been explored and demonstrated an
approximately 10-month PFS advantage; however, the
regimen was abandoned because of an unacceptable rate of
veno-occlusive disease [10]. As of yet, there are no other large
randomized studies comparing the MEL200 to a more
intensive cytotoxic regimen in MM.
Bendamustine is a synthetic chemotherapeutic agent that
combines the alkylating properties of a mustard group with
the antimetabolic activity of a purine analog. It can induce
responses in disease resistant to other alkylating agents via
direct induction of apoptosis, inhibition of mitosis, and
activation of an alternative DNA repair pathway distinct from
standard alkylator mechanisms of action [11]. Bendamustine
has proven activity in both newly diagnosed and in relapsed
or refractory MM. In newly diagnosed MM, the combination
of bendamustine and prednisone was shown to be superior
to melphalan and prednisone, with a longer time to treat-
ment failure (14 versus 10 months) and a higher CR rate (32%
versus 13%) [12]. For relapsed or refractory MM, bend-
amustine in combination with thalidomide and dexameth-
asone was shown to have an overall response rate of 26% in
a group of heavily pretreated patients (median 5 prior lines
of therapy) [13]. A French compassionate-use program
summary on the efﬁcacy of single-agent bendamustine in
a similar group of MM patients after relapse from multiple
prior therapies (including alkylators, steroids, IMiDs, and
bortezomib) reported an overall response rate of 30%, withTransplantation.
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phase 1/2 study of the bendamustine þ lenalidomide þ
dexamethasone combination in relapsed or refractory MM
showed encouraging activity with an overall response rate of
76% in a patient population that had a median of 3 prior
therapies [15]. Bendamustine also has demonstrated activity
in MM after relapse from ASCT, with an overall response rate
of 55% and PFS of 26 weeks, again intimating at a noncross
resistance with alkylating therapy [16]. The primary side
effects of bendamustine encountered in the mentioned
studies were due to bone marrow suppression; extra-
medullary toxicity is infrequent and usually mild.
We hypothesized that the addition of bendamustine
to ASCT conditioning in MM would enhance response
without a signiﬁcant increase in toxicity. Bendamustine has
already been shown to be a feasible part of a modiﬁed
BeEAM (bendamustine, etoposide, cytarabine, melphalan)
ASCTconditioning regimen for non-Hodgkin lymphomawith
acceptable safety and promising efﬁcacy [17]. We now report
the results of a phase 1 study adding escalating doses of
bendamustine to the melphalan 200 mg/m2.METHODS
Eligibility
Patients were eligible to participate if they had pathologically
conﬁrmed active MM, received prior induction therapy, age >18 years, life
expectancy >12 weeks, and at least 2  106 CD34þ hematopoietic stem cells
mobilized in preparation for ASCT. Eligibility for ASCT included Karnofsky
performance status 70%, left ventricular ejection fraction >40%, lung
diffusion capacity >45%, creatinine clearance >60 cc/min, and no other
active infections, pregnancy, or other major health concerns. Additional
eligibility criteria included serum aspartate aminotransferase and alanine
aminotransferase less than 5 times the upper limit of normal and serum
total bilirubin less than 3 times the upper limit of normal. The study
was approved by the Institutional Review Board of theWeill Medical College
of Cornell University, New York Presbyterian Hospital-Cornell Medical
Center, in accordance with federal regulations and the Declaration of
Helsinki. All patients signed written informed consent before study enroll-
ment. This trial was registered at ClinicalTrials.gov, identiﬁer:NCT00916058.Conditioning Regimen and Supportive Care
Increasing doses of bendamustine were added to high-dose melphalan
(melphalan 100 mg/m2 daily on day -2 and day -1) according to a modiﬁed
Fibonacci schedule in a 3þ3 phase 1 study design until onset of dose-
limiting toxicity (DLT). Dose escalation of bendamustine was performed
according to a modiﬁed Fibonacci scheme. The following bendamustine
cohorts were studied: (1) 30 mg/m2 given on day -1; (2) 60 mg/m2 on day
-1; (3) 90 mg/m2 on day -1; (4) 60 mg/m2 on days -2 and -1 (total dose
120 mg/m2); (5) 90 mg/m2 on day -2 and 60 mg/m2 on day -1 (total dose
150 mg/m2); and (6) 125 mg/m2 on day -2 and 100 mg/m2 on day -1 (total
dose 225 mg/m2). Dose escalation of bendamustine was limited to
a maximum of 225 mg/m2 because of a prior report of cardiac toxicity in
patients receiving bendamustine at a dose of 280mg/m2 once every 3 weeks
as a single agent to treat solid tumors [18]. Three subjects were enrolled in
each cohort; if a dose-limiting toxicity (DLT) was encountered at a particular
dose level, the cohort at this dose level was expanded to 6 patients. If 2 DLTs
occurred in the same dose level, the prior dose level was deﬁned as the
maximum tolerated dose. If no maximum tolerated dose was found at any
dose level, the plan to was to expand the highest dose level (cohort 6) to
reach a study total of 25 patients to further evaluate safety.
Patients were followed prospectively for adverse events from the start
of conditioning (day -2) through day þ100 from ASCT. Toxicities were
assessed on a daily basis starting from the beginning of conditioning
chemotherapy until hospital discharge; thereafter, toxicities were assessed
on a monthly basis. All adverse events were ﬁrst documented by the study
transplant physicians (Tomer Mark, MD, MSc; Usama Gergis, MD; Roger
Pearse, MD, PhD; Sebastian Mayer, MD; Koen Van Besien, MD, PhD; and
Tsiporah Shore, MD) and thereafter collated and graded by 2 independent
reviewers, (Tomer Mark, MD, MSc and Whitney Reid, BA) according to the
National Cancer Institute Common Terminology Criteria for Averse Events
version 4.0 (CTCAEv4). DLT in a cohort was deﬁned as any grade 3 CTCAEv4
nonhematologic adverse event that did not resolve within 72 hours or any
occurrence of a grade 4 CTCAEv4 nonhematologic adverse event. In addition,failure to engraft with an absolute neutrophil count of 500/ml and platelet
count of 20,000/ml untransfused by day 35 were considered DLTs.
Oral cryotherapy with ice chips was offered to each subject during
melphalan infusion. Stem cell infusion of at least 2 x 106 CD34þ cells/kg was
performed at 24 to 48 hours after the last dose of melphalan. All patients
received granulocyte colony-stimulating factor support starting dayþ1 until
absolute neutrophil count (ANC) exceeded 1000 cells/ml for 48 hours.
Patients received levoﬂoxacin, acyclovir, and ﬂuconazole antimicrobial
prophylaxis starting day þ1, red blood cell and platelet transfusions as
needed, and other supportive care as an inpatient from the ﬁrst dose of
chemotherapy until white blood cell engraftment, deﬁned as ANC>1000/ml.
Response Determination
Serum and urine protein electrophoresis with immunoﬁxation as well as
free light chain determinations were done before transplantation, day þ30,
day þ60, and thereafter every 6 months to assess disease response as per
International Myeloma Working Group (IMWG) criteria [19]. Bone marrow
biopsy and skeletal imaging, either by skeletal survey or positron emission
tomography-computed tomography scan, were performed before and
100 days after stem cell infusion to further assess baseline and post-ASCT
disease status. Karyotyping and ﬂuorescent in situ hybridization (FISH)
were performed on each bone marrow aspirate sample. PFS was deﬁned as
time elapsed between the stem cell infusion (day 0) and disease progression.
OS was deﬁned as time elapsed between day 0 and death from any cause.
Study Design and Statistical Analysis
The primary endpoint of this study was to determine the maximum
tolerated dose of bendamustine added to high-dose melphalan via a stan-
dard 3þ3 phase 1 design. Secondary endpoints included overall response
rate, PFS, and OS. Overall response rate was determined for each enrolled
subject on the intent-to-treat principle. PFS and OS were estimated
according to the Kaplan-Meier method. A Cox proportional hazards
regression model was used to evaluate the impact of tumor and patient
characteristics on survival outcomes. All P values are 2-sided with statistical
signiﬁcance evaluated at the .05 a level. All analyses were performed in Stata
version 10.1 (Stata Corporation, College Station, TX).
RESULTS
Study Population
A total of 25 transplant-eligible patients who had
received prior induction therapy for MM were enrolled and
constituted the treatment population. All patients were fol-
lowed for toxicity, stem cell engraftment, and treatment
response. Patient baseline demographics and disease char-
acteristics are summarized in Table 1. Brieﬂy, patients had
amedian age of 56 (range, 37 to 65). Intermediate (stage II) or
high-risk (stage III) disease was present in 75% of patients by
Durie-Salmon criteria and in 55% of patients as deﬁned
by the International Staging System (ISS). The isotype
distribution of M-proteins reﬂected the typical MM pop-
ulation (IgG, 64%; IgA, 24%; free light chain-only, 12%).
Karyotype and FISH analyses were performed in all patients.
High-risk cytogenetic abnormalities, deﬁned as the presence
of any 1 or more of the following were detected in 28% of
the patients: del(17p), t(4;14), t(14;16), amp(1q), del(1p),
complex karyotype, and del(13q) karyotype. Extramedullary
myeloma was present in 20% of patients. When possible,
a Ki67 score was generated by immunohistochemical cos-
taining of CD138 and Ki67 [20]. A high Ki67 score of 10%
was detected by immunohistochemistry in 32% of patients,
indicating particularly high-risk disease. Treatment history
before transplantation was collected for each patient. A prior
line of therapy was deﬁned as a predetermined course of
treatment according to IMWG criteria [19]. Median number
of prior lines of therapy was 1, (range, 1 to 3). All patients had
received a novel agent at some point during induction
therapy, either lenalidomide (68%) or bortezomib (64%),
alone or in combination, although fewer had regimens
including thalidomide (20%), liposomal doxorubicin (16%),
or an alkylating agent, such as cyclophosphamide (24%).
Patient response to induction therapy just before
Table 2
Stem Cell Collection and Engraftment
Mobilization regimen, n (%)
G-CSF alone 4 (16)
G-CSF þ plerixafor 14 (56)
G-CSF þ alkylating chemotherapy 7 (28)
Median number of CD34þ cells reinfused, n (range) 4.22 (2.68-12.66)
Median days until ANC >1000/ml, n (range) 11 (9-14)
Median days of G-CSF, n (range) 12 (9-15)
Median days until platelets >20 x 103/ml, n (range) 13 (10-21)
Median days to hospital discharge, n (range) 14 (11-22)
G-CSF indicates granulocyte colony-stimulating factor; ANC, absolute
neutrophil count.
Table 1
Patient and Disease Characteristics (N ¼ 25)
Median age, y (range) 56 (37-65)
Sex, n (%)
Male 14 (56)
Female 11 (44)
Durie-Salmon classiﬁcation, n ¼ 24, (%)
Stage Ia 6 (25)
Stage IIa 7 (29)
Stage IIIa 8 (33)
Stage IIIb 3 (13)
International Staging System Classiﬁcation, n ¼ 20, (%)
Stage I 9 (45)
Stage II 7 (35)
Stage III 4 (20)
Immunoglobulin Isotype, n (%)
IgG-k 12 (48)
IgG-l 4 (16)
IgA-k 3 (12)
IgA-l 3 (12)
Free k 2 (8)
Free l 1 (4)
Karnofsky performance status before ASCT, n (%)
100 6 (24)
90 12 (48)
80 5 (20)
70 1 (4)
60 1 (4)
Cytogenetic risk category, n (%)*
Low risk 18 (72)
High risk 7 (28)
Ki67 score, n ¼ 22, n (%)y
10% 7 (32)
<10% 15 (68)
Presence of extramedullary disease, n (%)
Yes 4 (16)
No 21 (84)
Lines of prior therapy, n (%)
1 19 (76)
2 2 (8)
3 4 (16)
Therapy exposure history, n (%)
Thalidomide 5 (20)
Lenalidomide 17 (68)
Bortezomib 16 (64)
Alkylating agent 6 (24)
Liposomal doxorubicin 4 (16)
Maximum disease response before ASCT, n (%)
Progression of disease 1 (4)
Partial response 6 (24)
Very good partial response 8 (32)
Complete response 5 (20)
Stringent complete response 5 (20)
* High-risk cytogenetics, [number of patients]: del 13q karyotype, [5]; del
17p, [1]; t(14;16), [1]; amp 1q or del 1p, [4]; complex karyotype, [5].
y Ki67 score is the ratio of Ki67 positive cells to CD138 cells on immu-
nohistochemical staining of the bone marrow aspirate.
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partial response in 24%, very good partial response in 32%, CR
in 20%, to stringent complete response in 20%.ASCT
Stem cell collection and engraftment data are listed
in Table 2. All 25 patients received peripheral blood hema-
topoietic stem cells, with the choice of mobilization regimen
at the discretion of the transplant physician. All patients
successfully engrafted. Median number of days to neutrophil
and platelet engraftment were 11 (range, 9 to 14) and
13 (range, 11 to 21), respectively. Median number of days on
granulocyte colony-stimulating factorwas 12 (range, 9 to 15).
Patients stayed in the hospital for a median of 14 days (range,
11 to 22) after stem cell infusion. The engraftment kineticsseen for escalating bendamustine and melphalan condi-
tioning in this study are similar to those reported previously
with a MEL200 conditioning regimen [21,22].
Nonhematologic Toxicity
All subjects were followed from day 0 through day 100 for
nonhematologic toxicity, with adverse events listed in
Table 3. All grade 4 events occurred in one subject in cohort
2 (bendamustine dose of 60 mg/m2 on day -1) and repre-
sented the single DLT in this study. The DLT seen was grade
4 respiratory compromise, which required ventilator support
for 24 hours in the setting of culture-negative neutropenic
sepsis. The same subject also experienced grade 3 parox-
ysmal atrial arrhythmia during the septic episode. The DLT
was not considered to be directly related to bendamustine.
All other grade 3 noninfectious toxicities listed in Table 3
occurred in 1 subject who experienced a hypersensitivity
reaction to platelet transfusion, resulting in transient hypo-
tension, hypoxia, and delirium which resolved in 24 hours
and was not considered to be a DLT.
Nearly all patients experienced mild nausea or vomiting
(88%); however, there were no grade 3 or grade 4 events.
Mucositis and gastrointestinal upset were mild in most
patients; only 2 out of 25 subjects (8%) experienced grade
3 mucositis and there was single case of grade 3 diarrhea
(4%). With the exceptions of the grade 4 atrial ﬁbrillation
seen in the instance of neutropenic sepsis, and a grade
3 hypotension associated with a hypersensitivity reaction
to platelet transfusion, there were no other grade 3 or grade
4 cardiac events. No cardiac events were directly attributable
to the bendamustine infusion. There were no cases of veno-
occlusive liver disease.
Thirteen patients (52%) had grade 1 or grade 2 fever and
a causative organism was identiﬁed in 6 (24%), including
1 with S. mitis bacteremia, 1 with E. coli bacteremia, 1 with
line-related S. haemolyticus infection, 1 with microsporidia
enterocolitis, and 1 with rotavirus enterocolitis, all of
which resolved with antibiotic therapy or supportive care
alone. There was 1 case of C. difﬁcile colitis. There was no
transplant-related mortality.
Response Assessment
Responses by IMWG criteria to induction therapy before
transplantation and at days 30, 60, 100, 6 months, and 1-year
post-ASCT are shown in Figure 1. Before transplantation, 40%
of the patients had achieved CR or better with induction
therapy. After transplantation, the CR and better rate
improved through 1 year of follow-up: 40% were in CR or
better at day 30; 46% at day 60; 42% at day 100; 47% at day
180, and 48% at 1 year. Overall response rate was 79% at day
100 after ASCT.
Table 3
Nonhematologic Averse Events (N ¼ 25)
Adverse Event Grade 1 n (%) Grade 2 n (%) Grade 3 n (%) Grade 4 n (%) Total n (%)
Gastrointestinal
Oral Mucositis 13 (52) 8 (32) 2 (8) 23 (92)
Diarrhea 17 (68) 4 (16) 1 (4) 22 (88)
Nausea or Vomiting 20 (80) 2 (8) 22 (88)
Anorexia 11 (44) 5 (20) 16 (64)
Dyspepsia 11 (44) 11 (44)
Constipation 5 (20) 1 (4) 6 (24)
Reﬂux 3 (12) 1 (4) 4 (16)
Xerostomia 4 (16) 1 (4) 5 (20)
Dysgeusia 3 (12) 2 (8) 5 (20)
Rectal bleeding 1 (4) 1 (4)
Infectious
Fever 10 (40) 3 (12) 13 (52)
Sepsis 1 (4) 1 (4)
Upper respiratory infection 1 (4) 1 (4)
Pneumonia 1 (4) 1 (4)
Oral thrush 2 (8) 2 (8)
C. difﬁcile colitis 1 (4) 1 (4)
Streptococcus mitus bacteremia 1 (4) 1 (4)
Staphylococcus haemolytica bacteremia, line related 1 (4) 1 (4)
Microsporidia enteritis 1 (4) 1 (4)
Rotavirus enterocolitis 1 (4) 1 (4)
E. coli bacteremia 1 (4) 1 (4)
Blepharitis 1 (4) 1 (4)
Tinea cruris 1 (4) 1 (4)
Tinea pedis 1 (4) 1 (4)
Sinusitis 1 (4) 1 (4)
Respiratory 1 (4)
Dyspnea 4 (16) 1 (4) 1 (4) 6 (24)
Cough 2 (8) 2 (8) 4 (16)
Hypoxia 1 (4) 1 (4)
Pleural effusion 1 (4) 1 (4)
Renal
Prerenal acute kidney injury 1 (4) 1 (4)
Dysuria 1 (4) 1 (4)
Cardiac
Palpitations 1 (4) 1 (4)
Peripheral edema 7 (28) 7 (28)
Hypotension 2 (8) 1 (4) 3 (12)
Hypertension 3 (12) 3 (12)
Atrial ﬁbrillation 1 (4) 1 (4) 2 (8)
Sinus tachycardia 1 (4) 1 (4)
Chest pain 1 (4) 1 (4)
Constitutional
Insomnia 1 (4) 1 (4)
Fatigue 6 (32) 10 (40) 16 (72)
Pruritis 4 (16) 1 (1) 5 (20)
Neurologic and psychologic
Headache 6 (24) 1 (4) 7 (28)
Dizzyness 3 (12) 3 (12)
Steroid psychosis 1 (4) 1 (4)
Delirium 1 (4) 1 (4) 2 (8)
Peripheral neuropathy 5 (20) 2 (8) 7 (28)
Anxiety 4 (16) 4 (16)
Musculoskeletal
Myalgia 8 (36) 8 (36)
Arthralgia 5 (20) 4 (16) 9 (36)
Generalized weakness 2 (8) 2 (8)
Other
Nipple sensitivity 2 (8) 2 (8)
Rash 4 (16) 2 (8) 6 (24)
Flushing 2 (8) 2 (8)
Blurred vision 2 (8) 2 (8)
Patients were followed for adverse events from the start of conditioning (day -2) through dayþ100 from ASCT. All adverse events were graded by 2 independent
reviewers according to the National Cancer Institute Common Terminology Criteria for Averse Events version 4.0.
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detected at day 100, all with high-risk prognostic factors.
Two progressing patients initially presented with extra-
medullary myeloma; 1 subject had ISS stage III disease
with complex karyotypic abnormalities and plasmablastic
morphology with a Ki67 immunohistochemical positivity in19.4% of plasma cells on initial bone marrow biopsy; and the
remaining 2 subjects were heavily pretreated (3 prior lines of
therapy) after becoming refractory to both lenalidomide and
bortezomib. Two of the patients with early progression of
disease were in cohort 1, and cohorts 2, 4, 5 had 1 patient
each. Two patients, also with high-risk disease features, had
Figure 1. Myeloma response (IMWG Criteria). IMWG indicates International
Myeloma Working Group; ASCT, autologous stem cell transplantation; sCR,
stringent complete response; CR, complete response; VGPR, very good partial
response; PR, partial response; POD, progression of disease.
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up. One patient in cohort 2 who progressed had Durie
Salmon stage IIIb IgA-kappa myeloma and a Ki67 on initial
bone marrow biopsy of 42%. The second patient, who was in
cohort 6, had IgA-lambda myeloma, Durie Salmon stage IIa,
ISS stage III, with t(14;16) detectable on FISH testing, and
a Ki67 on initial bone marrow biopsy of 13%.Figure 2. Progression-free (A) and overall (B) survival. (A) N ¼ 25 patients, 11
with progression of disease. Median progression-free survival, 791 days (95%
CI, 351-NR). (B) N ¼ 25 patients, 6 deaths. Median overall survival not reached.
2-year overall survival ¼ 70% (95% CI, 43.9%-85.7%).Clinical Outcomes
After a median of 473 days (range, 279 to 1128) of follow-
up post-ASCT, 10 patients had progressed. Median PFS was
791 days (95% CI, 351-NR) (Figure 2). Six patients died during
the course of the study, all from progressive myeloma and
resulting complications. All deaths occurred beyond 100
days posttransplantation. Median overall survival was not
reached. Actuarial 2-year OS was 70% (95% CI, 43.9% to 85.7%)
(Figure 2). Maintenance therapy was given at the discretion
of the referring physician. Seven out of the 20 patients
without progression at day 100 subsequently started main-
tenance therapy: 6 with lenalidomide 10 to 15mg daily and 1
with weekly bortezomibmaintenance. None of the 7 patients
who received post-ASCT maintenance had disease progres-
sion during the follow-up period.
A multivariate Cox proportional hazards model evaluated
the effect of multiple prognostic patient and tumor charac-
teristics on PFS and OS. The only risk factor with signiﬁcant
impact of risk of progression was the presence of high-risk
cytogenetics (HR, 4.81; P ¼ .025), although no one factor
made a signiﬁcant impact on OS.DISCUSSION
High-dose chemotherapy followed by stem cell rescue
was shown to be superior to conventional chemotherapy in
a number of randomized clinical trials [1]. Although several
attempts have been made to optimize the conditioning
regimen ASCT in multiple myeloma since the standard
MEL200 gained widespread acceptance, no one regimen has
thus far shown clear superiority to this standard without
adding to toxicity. Yet, there is suggestive evidence that more
intense chemotherapy may be useful for prolonging PFS and
OS in myeloma. The IFM 9502 randomized study comparing
TBI þ melphalan 140 mg/m2 to melphalan 200 mg/m2
provides compelling evidence that the increased dose of
melphalan leads to superior overall survival (45.6% versus65% survival at 45 months) despite equivalent treatment-
related mortality [1]. The IFM 99-04 protocol showed
a superior outcome in the tandem MEL200 group in those
patients who failed to achieve a very good partial response or
better after a single transplant [23]. Amifostine has been
used to safely increase total melphalan dose up to 300 mg/
m2 in B-cell lymphoma with acceptable toxicities [24]. The
initial report of a randomized phase 1/2 study comparing
MEL200 versusMEL280þ amifostine as conditioning for ﬁrst
ASCT in MM demonstrates higher rates of CR and near CR,
albeit with more regimen-related gastrointestinal toxicity in
the MEL280 arm [25]. It remains to be seen whether the
higher rate of major responsewith MEL280þ amifostine will
translate into longer PFS and OS.
Bendamustine has been shown to overcome resistance to
alkylating chemotherapy in lymphoma refractory to alky-
lating agents [11,26]. Bendamustine also has documented
activity in MM in a number of settings, including combina-
tion therapy with novel agents, in refractory disease, and
after relapse from prior stem cell transplant [13,16]. A recent
phase 1/2 study reported favorable results for the substitu-
tion of bendamustine in place of BCNU (carmustine) in the
BEAM (BCNU, etoposide, cytarabine, melphalan) condi-
tioning regimen for relapsed or refractory lymphoma,
showing an 81% CR rate at 18 months and a toxicity proﬁle
that is not signiﬁcantly worse compared to BEAM [17].
We explored whether bendamustine could be safely
added to a high-dose melphalan regimen in this phase
T.M. Mark et al. / Biol Blood Marrow Transplant 19 (2013) 831e8378361 study. Escalating doses of bendamustine were added
through 6 cohorts to split-dose melphalan at 200 mg/m2
without encountering a maximum tolerated dose. The choice
to split the melphalan into 2 subsequent daily doses of 100
mg/m2 each was made to reduce the risk of synergistic
toxicity between the melphalan and bendamustine. A sole
DLT occurred, an episode of sepsis with rapid atrial ﬁbrilla-
tion, which was not directly attributable to the use of bend-
amustine. Toxicities were not signiﬁcantly different than
those expected with MEL200, consisting primarily of mild
mucositis, nausea, and fatigue. The historically reported rates
of all grades of oral mucositis in subjects receiving high-dose
melphalan have varied widely from 40% to 90% [21,27,28]. In
a recent study comparing palifermin versus placebo for use in
high-dose melphalan therapy, the overall incidence of WHO
grades 1 to 4 mucositis in the placebo arm (N ¼ 57) was 75%,
with the rate of grades 3 and 4 mucositis at 19% and 18%
respectively [29]. In another recent phase 1 study evaluating
dose escalation of palifermin in subjects receiving MEL200
conditioning, the rate of grade 3 mucositis was 44% [30].
Avivi et al., in a study of mucosal and salivary gland integrity
in 25 consecutive subjects treated with MEL200, report an
overall oral mucositis rate of 96% [31]. In our study, oral
mucositis occurred in 92% of subjects, yet the rate of severe
mucositis was only 8%. Given this data, bendamustine does
not appear to signiﬁcantly elevate mucositis risk from
MEL200. Bendamustine-induced serious cardiotoxicity was
not seen and treatment-related mortality was 0% at 100 days
posttransplantation. Engraftment kinetics did not signiﬁ-
cantly differ from those expected after MEL200; there were
no cases of prolonged or failed engraftment.
This is a phase 1 study, involving a heterogeneous group
of patients with MM presenting for ﬁrst transplantation and
was not designed to evaluate regimen efﬁcacy or the added
contribution of bendamustine. All patients had received at
least 1 of the novel agents during induction, but a variety of
induction regimens were used and approximately 25% had
received multiple lines of therapy before transplantation,
thereby obfuscating response and PFS results. It is too early
to draw deﬁnitive conclusions regarding the efﬁcacy of
bendamustine in ASCT for MM, or a dose-response rela-
tionship based on this study. We have reported an overall
response rate of 80% at day 100 and a CR or better rate of
approximately 45% at 1-year post-ASCT. The median PFS of
791 days (26 months) is on par with what is expected
with MEL200, as is the OS rate of 70% at 2 years
posttransplantation. The 6 patients in the study who died all
died more than 100 days post-ASCT of progressive MM. Each
patient who died had features delineating particularly
aggressive MM, such as high-risk cytogenetics or extra-
medullary disease. Of all analyzed prognostic factors, only
high-risk cytogenetics predicted higher risk of disease
progression.
In conclusion, the addition of bendamustine to a high-
dose melphalan regimen at a total dose of 225 mg/m2 does
not increase transplantation risk or toxicity in multiple
myeloma. This regimen is currently being explored for efﬁ-
cacy in a phase 2 study.
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